23 May 2013
Keywords: medarex, aids, drug, clears, hurdle, mdx-240, bispecific
Article | 18 March 1996
Medarex' MDX-240, a bispecific antibody therapeutic for the treatment of
HIV-infected patients, was well tolerated and provoked a transient
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
22 May 2013
© 2013 thepharmaletter.com